Asunto(s)
Predisposición Genética a la Enfermedad/genética , Polimorfismo de Nucleótido Simple/genética , Factor de Necrosis Tumoral alfa/genética , Síndrome de Behçet/genética , Estudios de Casos y Controles , Frecuencia de los Genes , Antígenos HLA-B/genética , Antígeno HLA-B51 , Humanos , Líbano , Regiones Promotoras Genéticas/genéticaRESUMEN
OBJECTIVE: To assess the presence of Chlamydia pneumoniae DNA in the joints of patients with reactive arthritis (ReA) and other arthritides. METHODS: DNA was prepared from synovial tissue (ST) and several synovial fluid (SF) samples from 188 patients with either ReA, undifferentiated oligoarthritis, or other forms of arthritis, and from 24 normal (non-arthritis) individuals. Preparations were screened using polymerase chain reaction (PCR) assays that independently targeted the C. pneumoniae 16S ribosomal RNA and major outer membrane protein genes. RESULTS: Twenty-seven of 212 ST samples (12.7%) were PCR positive for C. pneumoniae DNA; 10 SF samples from these 27 patients were similarly positive. Among the PCR-positive patients, 3 had ReA, 2 had Reiter's syndrome, 7 had undifferentiated oligoarthritis, 4 had undifferentiated monarthritis, 6 had rheumatoid arthritis, and 5 had other forms of arthritis. No samples from normal control individuals were PCR positive. CONCLUSION: DNA of C pneumoniae is present in synovial specimens from some arthritis patients. The prevalence of this organism in the joints was lower than that of C trachomatis, and synovial presence of the organism was not associated with any distinct clinical syndrome. Widely disseminated nucleic acids such as those of C. pneumoniae might have some role in the pathogenesis of several arthritides, since the organism was not found in the ST from normal control individuals.
Asunto(s)
Artritis Reumatoide/genética , Infecciones por Chlamydia/genética , Chlamydia trachomatis/genética , Chlamydophila pneumoniae/genética , Líquido Sinovial/microbiología , Membrana Sinovial/microbiología , Artritis Reactiva/etiología , ADN Bacteriano/análisis , Humanos , Articulaciones/química , Reacción en Cadena de la Polimerasa , Prohibitinas , Líquido Sinovial/química , Membrana Sinovial/químicaRESUMEN
Genetically determined differences in interleukin-10 (IL-10) and gamma interferon (IFN-gamma) responses in mice correlate with clearance of Chlamydia pneumonitis infection. We measured the synovial expression of IL-10 and IFN-gamma and additional cytokine genes in patients who had recent-onset Chlamydia-associated arthritis (Chl-AA). IL-10 and IFN-gamma mRNA were relatively abundant in recent-onset Chl-AA.
Asunto(s)
Artritis Infecciosa/genética , Artritis Infecciosa/inmunología , Infecciones por Chlamydia/genética , Infecciones por Chlamydia/inmunología , Chlamydia/patogenicidad , Interferón gamma/genética , Interleucina-10/genética , Adulto , Animales , Artritis/genética , Artritis/inmunología , Artritis Infecciosa/etiología , Estudios de Casos y Controles , Chlamydia/genética , Chlamydia/aislamiento & purificación , Infecciones por Chlamydia/etiología , Citocinas/genética , ADN Bacteriano/genética , ADN Bacteriano/aislamiento & purificación , Femenino , Expresión Génica , Humanos , Masculino , Ratones , Persona de Mediana Edad , ARN Mensajero/genética , ARN Mensajero/metabolismo , Membrana Sinovial/inmunologíaRESUMEN
OBJECTIVE: To assess the value of a new short biopsy needle modified from the Parker-Pearson needle in obtaining adequate synovial tissue from small joints. METHODS: The short needle is 2.5 cm in length with a repositioned hooked biopsy notch closer to the end of the needle to allow better specimen retrieval. It can be used to obtain synovial biopsies from small joints of the hand using the usual arthrocentesis approaches. RESULTS: Ten patients underwent 12 synovial biopsies with a success rate of 92%. No complications from the procedure were observed. Samples obtained were adequate for a variety of studies including synovial histopathological evaluation, electron microscopy, and DNA extraction. CONCLUSION: The new modified short needle expands the spectrum of joints that can be biopsied for diagnostic and research purposes in an outpatient setting.
Asunto(s)
Artritis Reumatoide/patología , Biopsia con Aguja/instrumentación , Articulaciones de los Dedos/patología , Membrana Sinovial/patología , Diseño de Equipo , Estudios de Evaluación como Asunto , Femenino , Humanos , Masculino , Psoriasis/patologíaRESUMEN
It has been reported that the mRNA of the type 1 cytokine, interferon-gamma (IFN-gamma)--but not the type 2 cytokine interleukin-4 (IL-4)--is detected in synovial tissues of rheumatoid arthritis (RA) patients, whereas both IFN-gamma and IL-4 mRNA are detected in reactive arthritis (ReA). To evaluate such data more extensively, we obtained 208 synovial specimens in a prospective study of 52 early synovitis patients (13 RA, 11 ReA, 28 undifferentiated oligoarthropathy) and analyzed type 1 and type 2 cytokine mRNA expression in specimens containing sufficient mRNA. Using a nested reverse transcriptase polymerase chain reaction technique, we measured the relative mRNA levels of 10 cytokines and CD3 delta chain. We detected IL-10, IL-15, and CD3 delta chain mRNA in all RA and ReA patients and frequently detected tumor necrosis factor-alpha, IL-1 beta, and IFN-gamma mRNA. IL-6 and IL-12 p40 mRNA were detected in approximately one-half of the patients. We also detected greater amounts of IL-2 and IFN-gamma mRNA in ReA than were detected in RA. However, we rarely detected IL-4 or IL-13 mRNA. Similar cytokine profiles were observed in undifferentiated oligoarthropathy. The amounts of cytokine mRNAs, except for IL-10, in specimens from the patients taking prednisone or second-line antirheumatic drugs tended to be less than in specimens from the patients taking neither prednisone nor second-line antirheumatic drugs. These results suggest that cytokine mRNA profiles in patients with RA, ReA, and undifferentiated arthritis in their early stages are skewed toward proinflammatory macrophage-derived and type 1 cytokines. IL-10--not IL-4 or IL-13--mRNA appears to be the major antiinflammatory cytokine mRNA. Drug therapy is associated with depressed proinflammatory and type 1 cytokine mRNA production. The differences in the expression of IL-2 and IFN-gamma mRNA between RA and ReA may reflect unique etiological or host factors associated with the early stages of these diseases.